Leerink Partners: 'We expect MDT to trade higher tomorrow'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
July 11, 2025 12:26 PM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "On Thursday, July 10th, the Centers for Medicare and Medicaid Services (CMS) released a proposed Decision Memo to cover Renal Denervation (RDN) -- either radiofrequency (Medtronic) or ultrasound-based (Recor Medical, a subsidiary of... More
Raymond James Reiterates Market Perform Rating on Medtronic, Inc. (MDT)
July 11, 2025 8:22 AM EDTRaymond James analyst Jayson Bedford reiterated a Market Perform rating on Medtronic, Inc. (NYSE: MDT).
The analyst comments "CMS released its proposed National Coverage Determination (NCD) for Renal Denervation (RDN) last night (here). An NCD provides necessary scope around clinical eligibility for reimbursement purposes. The timeline was expected (on/before July 11). This document triggers another 30-day comment period, culminating with a final NCD expected to be published on/around October 8, 2025. Punchline: We believe the document reads well with no unexpected restrictions. CMSs inclusion threshold of 140 mmHg ambulatory blood pressure (which we believe equates... More
BTIG Comments on Medtronic, Inc. (MDT)
July 11, 2025 6:01 AM EDTBTIG analyst Sean Lavin reiterated a Neutral rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "WHAT YOU SHOULD KNOW: Announced today, CMS provided its proposed National Coverage Decision (NCD) for Renal Denervation (RDN). As anticipated, CMS is proposing to cover RDN for uncontrolled hypertension. Even though this was anticipated we think it's still a win for Medtronic (MDT, Neutral) who has been preparing sites for coverage with the launch of Symplicity Spyral as it ramps up outpatient hypertension programs. We run through the criteria included in... More
Evercore Comments on Medtronic (MDT)
July 11, 2025 5:57 AM EDTEvercore Comments on Medtronic (NYSE: MDT)
The analyst comments "Today, CMS published in proposed NCD decision memo for Renal Denervation (RDN). Here are the details: Coverage Criteria: CMS proposed coverage for RF and ultrasound renal denervation (RDN) for pts with >140/90mm Hg and uncontrolled hypertension (rHTN) under coverage with evidence development (CED) see Fig 1. CED process notes study must incl. >1 BP endpoints (e.g. ASBP) and adverse events (e.g. mortality/worsening renal... More
